Pulmonx Q3 2026 Earnings Conference Call - PULMONX CORP

Financial Performance:

• Third quarter 2026 worldwide revenue reached $22.8 million, a 6% year-over-year (YoY) increase from $21.5 million, marking the return to growth since mid-2025.
• U.S. revenue grew 7% YoY to $14.9 million, while international revenue increased 5% YoY to $7.9 million (6% constant currency).
• Non-China international markets grew approximately 9% YoY.
• Gross margin improved to 76% in Q3 2026 from 75% the prior year, driven by lower distributor mix and supply chain efficiencies; full-year 2026 guidance is set at ~77%.
• Operating expenses decreased 18% YoY to $24.9 million; excluding non-cash stock-based compensation ($3.2 million), OpEx fell 16% YoY.
• Full-year 2026 operating expenses are guided to $108–$109 million.
• Adjusted EBITDA loss narrowed nearly 60% YoY to $3.5 million from $8.2 million.
• Net loss reduced 40% YoY to $8.4 million ($0.19/share), down from $14 million ($0.34/share).
• Cash and cash equivalents ended September 30, 2026, at $52.7 million; full-year cash burn is expected to be ~$22 million, a 30% reduction from 2025.
• Credit facility restructuring extended debt maturity to 2031 with access to an additional $20 million undrawn capital subject to milestones.

Guidance and Future Outlook:

• Reiterated full-year 2026 revenue guidance of $90–$92 million, implying Q4 growth in the double digits.
• Confirmed commitment to sustaining double-digit growth long-term but declined to provide specific 2027 guidance, deferring to next quarter's update.
• Full-year 2026 gross margin guidance revised to approximately 77% due to persisting supply chain efficiencies.
• Management expects cash burn to improve further in 2027 driven primarily by top-line growth and operating leverage rather than further cost cuts.
• AeroSeal commercial launch outside the U.S. is targeted for 2027 in Europe (limited launch), with material revenue expected in 2028.
• China commercial activity is expected to resume shipments in early 2027, contributing approximately 2% of global revenue.

Business Segments and Product Lines:

• Added eight new U.S. treating centers during Q3.
• Completed filling substantially all open U.S. sales positions, shifting focus to productivity and retention.
• AeroSeal Convert2 IDE trial enrollment is on track to complete in the second half of 2027, potentially expanding the Total Addressable Market (TAM) by 20%.
• Digital advertising efforts successfully reduced cost per patient engagement and increased yield to treatment.
• U.S. sales team composition is transitioning toward promoting Territory Account Managers (TAMs) to Territory Managers, resulting in high-performing teams in key regions.

Market and Competitive Landscape:

• Strong scientific engagement noted at the European Respiratory Society Congress (Barcelona) and the American Association of Bronchoscopy and Interventional Pulmonology (Denver) regarding bronchoscopic lung volume reduction and the LIBERATE trial five-year data.
• U.S. market focus remains on "near-to-far" strategy: prioritizing high-quality valve programs, physician education, and direct-to-patient efforts in geographies with established centers.
• Competitive advantage cited through refined execution, disciplined selling activities, and a rebuilt sales organization.
• China market represented a lumpy, distributor-based 3% of revenue in Q3, with recent regulatory challenges (tariffs, registration) resolved, allowing for re-entry.

Risks and Challenges:

• China market volatility due to its distributor model and smaller revenue footprint (approx. 2% projected).
• Sales force turnover and variability in ramp-up times for new hires, with current mean tenure at 1.8 years.
• Potential drag on gross margins from China's return, though margins are expected to remain above 75%.
• Dependence on execution of the rebuilt U.S. sales team to sustain the projected double-digit Q4 growth.

Management Commentary and Tone:

• Tone was highly confident and positive, emphasizing the successful "rebuilding" of the commercial foundation and disciplined execution.
• Management expressed strong conviction in achieving the full-year revenue guidance and delivering operating leverage.
• Emphasis placed on the "near-to-far" framework as a key driver of recent success and future growth.
• Executive leadership highlighted the strategic shift to a leaner cost structure without sacrificing R&D or commercial investments.

Analyst Questions and Answers:

• Growth Drivers (John Young): Q3 growth was attributed to a rebuilt sales team, filled territories, and overcoming seasonal softness; difficult to isolate specific DTC vs. rep productivity contributions but described as encouraging.
• Sales Force Tenure: Current mean tenure is 1.8 years (down from 3 years pre-restructuring); management noted junior reps are ramping up successfully, with promoted TAMs leading growth in specific regions.
• China Impact: Clarified China represents a modest 2% of business; its return is expected early 2027 and is accounted for within 2026 guidance.
• Spending Strategy: Management indicated the current cost structure is sustainable with only minor inflation-driven increases; no significant reinvestment in OpEx is expected as revenue grows.
• 2027 Outlook: No specific 2027 guidance provided; reiterated commitment to double-digit growth and confidence in consensus estimates.
• New vs. Reactivated Accounts: New reps are effectively reactivating dormant accounts and driving same-store sales growth; new account openings remain at a target of ~40 per year.
• Cash Burn Trajectory: Expected to narrow further in 2027 driven by operating leverage and gross margin stability; management expressed confidence in a pathway to cash flow break-even.

Other Key Points:

• The LIBERATE pivotal trial's five-year follow-up data was presented at the AABIP meeting in Denver.
• Pulmonix is focusing on expanding its addressable market through AeroSeal, targeting a 20% global TAM expansion.
• The company reported 99% direct sales mix in Q3, contrasting with the more lumpy nature of its distributor markets.